Absorption of apomorphine by various routes in parkinsonism.
We wanted to determine the absorption and clinical effect of sublingual (SL) and transdermal apomorphine in parkinsonism. Patients received single SL apomorphine doses (N = 7) and the absorption was compared with parenteral (N = 5) and oral (N = 4) doses. One patient received a transdermal dose of apomorphine. The relative bioavailability of SL apomorphine ranged from 10 to 22% of a parenteral apomorphine dose. Oral apomorphine was less than 4% bioavailable, and the transdermal dose did not produce detectable plasma levels. Three patients with motor fluctuations responded to SL apomorphine, with a latency to effect of 20-40 min and a duration of effect of 15-100 min. One patient used SL apomorphine as an adjunct with levodopa, and during 1 month reported a large decrease in "off" periods. We conclude that apomorphine is effectively absorbed by the sublingual route.
Department of Neurology, School of Medicine, Oregon Health Sciences University, Portland.
S T
ST
Gancher
J G
JG
Nutt
W R
WR
Woodward
D000042:Absorption; D000279:Administration, Cutaneous; D000284:Administration, Oral; D000286:Administration, Sublingual; D000818:Animals; D001058:Apomorphine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001682:Biological Availability; D004359:Drug Therapy, Combination; D007263:Infusions, Parenteral; D007980:Levodopa / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism
D007980:Levodopa; D001058:Apomorphine